Epizyme, Inc. to Present at Upcoming Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in upcoming September conferences.

• Citi 8th Annual Biotech Day at the Mandarin Oriental Hotel in Boston, Mass. on Wednesday, September 4^th
• JMP Securities Biotech Day at the Langham Hotel in Boston, Mass. on Friday, September 6^th at 11:00 a.m. ET.
• Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York, N.Y. on Wednesday, September 11^th at 8:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
• Stifel Nicolaus Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Mass. on Thursday, September 12^th at 2:05 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
• BioPharm America Conference at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 17^th at 2:45 p.m. ET in a panel discussion titled "Partnering: Thinking beyond the deal."
• Cancer Advance Boston at the Harvard Medical School in Boston, Mass. on Thursday, September 19^th at 3:00 p.m. ET in a panel discussion titled "Redefining Cancer: Insights from Cancer Stem Cells, Epigenetics, Immunotherapy and More."
• LES Annual Meeting at the Philadelphia Marriott Downtown in Philadelphia, Pa. on Monday, September 23^rd at 12:15 p.m. ET to receive the 2013 LES Deal of Distinction Award in the Life Sciences Sector.
• Discovery On Target 2013 at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 24^th at 11:45 a.m. ET, presenting on targeting histone methyltransferases in cancer therapy.
• BioCentury's NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, N.Y. on Friday, September 27^th at 9:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.